DONALD P. TSCHUDY, M.D.; MARIUS VALSAMIS, M.D.; C. RICHARD MAGNUSSEN, M.D.
Acute intermittent porphyria is an inborn error of metabolism characterized by the excretion of excess porphyrin precursors (porphobilinogen and usually δ-aminolevulinic acid) in the urine, and by sporadic attacks of neurologic dysfunction. The disease is complex, involving variable patterns of autonomic and peripheral neuropathy as well as central nervous system manifestations. There may be alterations in carbohydrate, lipid, water, and electrolyte metabolism in addition to clinically inapparent endocrine abnormalities. The fundamental defect is thought to be a 50% decrease of uroporphyrinogen I synthetase, the third enzyme of the heme biosynthetic pathway. This is associated with a marked increase of hepatic δ-aminolevulinic acid synthetase, the first and rate controlling enzyme of the pathway. The measurement of uroporphyrinogen I synthetase in erythrocytes now provides an enzyme diagnostic test for the disease. Two therapeutic approaches that may prove to reverse the fundamental disease process, at least in some patients, involve  a high carbohydrate intake, and  intravenous administration of hematin. The latter, only recently introduced, is now being investigated.
TSCHUDY DP, VALSAMIS M, MAGNUSSEN CR. Acute Intermittent Porphyria: Clinical and Selected Research Aspects. Ann Intern Med. ;83:851–864. doi: 10.7326/0003-4819-83-6-851
Download citation file:
Published: Ann Intern Med. 1975;83(6):851-864.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use